DSIJ Mindshare

Dr Reddy’s Laboratories Ltd announced the launch of Remdesivir along with its subsidiaries on Wednesday. The product is being launched under the brand name of Redyx in India. Additionally, it also announced the launch of over-the-counter (OTC) Diclofenac Sodium Topical Gel 1 per cent, the store brand version of Voltaren® Arthritis Pain in the US market.

Vodafone Idea Limited informed on Monday that after almost two years of merging as a single entity, it will now also have a single brand name. The company has announced the new brand to be called ‘Vi’ (read as ‘we’). The company believes that this integration of two brands is the largest telecom integration in the world.

Alembic Pharmaceuticals Limited announced on Monday that its wholly-owned subsidiary, Alembic Global Holding SA has received tentative approval from the United States Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Treprostinil Injection, 20 mg/20 ml (1 mg/ml), 50 mg/20 ml (2.5 mg/ml), 100 mg/20 ml (5 mg/ml), and 200 mg/20 ml (10 mg/ml), multiple-dose vials.

Strides Pharma Science Limited (Strides) announced on Thursday that its step-down wholly-owned subsidiary, Strides Pharma Global Pte Limited (Singapore) has received approval for Prednisone tablets USP, 1 mg from United States Food & Drug Administration (USFDA). The product is a generic version of Meticorten tablets, 1 mg of Schering Corporation.

Embassy Office Parks REIT, India’s first listed REIT and the largest in Asia by area, announced on Thursday that REIT will be included in FTSE EPRA Nareit Global Emerging Index with effect from September 21, 2020.